Stoelzle Glass Group’s Pharma division has developed a resource-efficient, safe and stable process for the production of Type II glass.

Over the past year, Stoelzle’s R&D Team has worked on the development of a process for Type II glass production used for acidic and neutral aqueous preparations be it parenteral or non-parenteral.

“Our intention was to develop a new process for inner treatment of soda silica glass to reduce the main weakness of the current two existing processes regarding stability and safety and to develop a process which also fits smaller bottles by enabling optimal dosing of the treatment,” said Mr Alexander Stern, CSCO Stoelzle Glass Group & Head of BU Pharma.

“In line with our goal of being the first-choice partner for the global pharmaceutical industry we have been working on broadening our range of pharma primary packaging to better serve our clients’ needs.

"Adhering to our overall group’s sustainability goals, we developed a process, which ensures a consistent high quality, guarantees a high level of work safety in production with a minimum impact on the environment," said Mrs Antonia Karamat, Deputy. Global Sales Director BU Pharma & Sales Director Medical & Laboratory.

Dr Niklas Zwettler, Head of R&D at Stoelzle Glass Group addeds: “With our process, we also aimed to overcome difficulties that other treatment technologies face with small containers sizes.

"Laboratory analysis and inline samplings of container sizes ranging from 6 to 250ml showed a good stability of the process over a range of filling volumes and adherence to all requirements of US and European Pharmacopoeias for Type II Glass."

Full production of Stoelzle Type II is aimed to start in June 2021 in one of Stoelzle pharma’s dedicated plants in Köflach, Austria.

The plant has two furnaces with a daily capacity of 270 tons of glass. Around 1.5 billion pieces of white, amber and green packaging glass are produced annually on 11 fully automated production lines.